Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Harvard Business School
Colorcon
Express Scripts
McKinsey

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR VOTRIENT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Votrient

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00334282 ↗ Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma Completed GlaxoSmithKline Phase 3 2006-04-01 To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC). Approximately 350-400 eligible patients will be stratified and randomized in a 2:1 ratio to receive either 800 mg pazopanib once daily or matching placebo. The study treatment will continue until patients experience disease progression, unacceptable toxicity or death. Primary objective of the study is to evaluate and compare the two treatment arms for progression-free survival. Principal secondary objective is to evaluate and compare the two treatment arms with respect to overall survival. Other objectives are overall response rate [complete response (CR) + partial response (PR)], rate of CR + PR + 6 months stable disease, and the incidence, severity and causality of adverse events and serious adverse events. Safety and efficacy assessments will be regularly performed on all patients. An Independent Data Monitoring Committee will be established to monitor safety during the course of the study and to evaluate interim efficacy data on overall survival.
NCT00388076 ↗ Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) Completed GlaxoSmithKline Phase 1 2006-04-28 Pazopanib will be given with TAXOL in one part, in another part pazopanib will be given with TAXOL and PARAPLATIN, and in a third part pazopanib will be given with TAXOL and lapatinib (patients separated in each part). Toxicity monitoring will enable us to find the largest dose of pazopanib daily that can be safely given in combination with the chemotherapy agents TAXOL and PARAPLATIN, and with lapatinib, as well as what side effects are likely to manifest when these agents are given together and whether the combination of pazopanib with chemotherapy, helps to treat different types of cancer. Another objective is to find out how much pazopanib, TAXOL, PARAPLATIN and lapatinib are in the blood at specific times after the agents are given. Collecting the blood samples requires that the patients remain in the vicinity of the clinic overnight on 2 occasions.
NCT00450879 ↗ Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery Terminated National Cancer Institute (NCI) Phase 1 2007-01-01 This pilot clinical trial studies how well pazopanib hydrochloride works in treating patients with breast cancer that is newly diagnosed or has come back at or near the same place as the original tumor and can be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by preventing the growth of new blood vessels necessary for tumor growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed.
NCT00454142 ↗ Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer Completed National Cancer Institute (NCI) Phase 2 2007-08-01 This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with stage IV or recurrent nasopharyngeal cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
NCT00454363 ↗ Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed National Cancer Institute (NCI) Phase 2 2007-03-01 This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Votrient

Condition Name

Condition Name for Votrient
Intervention Trials
Carcinoma, Renal Cell 7
Stage IV Renal Cell Cancer 7
Clear Cell Renal Cell Carcinoma 7
Ovarian Cancer 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Votrient
Intervention Trials
Carcinoma 29
Carcinoma, Renal Cell 26
Sarcoma 20
Neoplasms 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Votrient

Trials by Country

Trials by Country for Votrient
Location Trials
United States 543
Germany 57
Italy 41
Canada 39
United Kingdom 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Votrient
Location Trials
Texas 30
California 23
Michigan 20
Florida 20
Illinois 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Votrient

Clinical Trial Phase

Clinical Trial Phase for Votrient
Clinical Trial Phase Trials
Phase 4 2
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 68
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Votrient
Clinical Trial Phase Trials
Completed 61
Terminated 19
Active, not recruiting 14
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Votrient

Sponsor Name

Sponsor Name for Votrient
Sponsor Trials
National Cancer Institute (NCI) 35
GlaxoSmithKline 34
Novartis 14
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Votrient
Sponsor Trials
Other 106
Industry 74
NIH 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Colorcon
Mallinckrodt
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.